Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 6/2016

01-06-2016 | Original Article

Results of 20- versus 45-min post-infusion scalp cooling time in the prevention of docetaxel-induced alopecia

Authors: Manon M. C. Komen, Wim P. M. Breed, Carolien H. Smorenburg, Tjeerd van der Ploeg, S. H. Goey, Jacobus J. M. van der Hoeven, Johan W. R. Nortier, Corina J. G. van den Hurk

Published in: Supportive Care in Cancer | Issue 6/2016

Login to get access

Abstract

Purpose

For patients, chemotherapy-induced alopecia (CIA) is one of the most distressing side effects of treatment. Scalp cooling can prevent or minimise CIA; the results may depend on the duration of cooling. Since a previous study on post-infusion cooling time in patients treated with docetaxel chemotherapy found no difference between 90 and 45 min, we investigated whether hair-preserving results could be maintained with a shorter post-infusion cooling time.

Methods

In this prospective, multi-centre randomised study, 134 patients who started treatment with docetaxel 75–100 mg/m2 in a 3-weekly schedule were randomly assigned in a 1:1 ratio to a post-infusion cooling time of 45 or 20 min. The primary end point was the need for a wig or other head covering as assessed by the patient. A visual analogue scale (VAS) with a range from 0 (not tolerable) to 10 (very tolerable) was used to measure tolerance.

Results

Scalp cooling results were similar for 45- and 20-min post-infusion cooling times. Thirty-three out of 45 patients (73 %) treated with 20 min of post-infusion cooling did not need a form of head covering, compared with 41 out of 52 patients (79 %) treated with 45 min of post-infusion cooling (p = 0.5). The procedure was well tolerated (mean visual analogue score 8.3). Six patients stopped due to intolerance during the first treatment cycle.

Conclusions

A 20-min post-infusion cooling time is effective and tolerable for patients treated with scalp cooling to prevent docetaxel-induced alopecia.

Trial registration

Trialregister.nl Identifier, NTR 1856.
Literature
1.
Lemieux J, Maunsell E, Provencher L (2008) Chemotherapy-induced alopecia and effects on quality of life among women with breast cancer: a literature review. Psychooncology 17:317–328CrossRefPubMed
2.
Mols F, van den Hurk CJ, Vingerhoets AJ, Breed WP (2009) Scalp cooling to prevent chemotherapy-induced hair loss: practical and clinical considerations. Support Care Cancer 17:181–189CrossRefPubMed
3.
Rosman S (2004) Cancer and stigma: experience of patients with chemotherapy-induced alopecia. Patient Educ Couns 52:333–339CrossRefPubMed
4.
van den Hurk CJ, Mols F, Vingerhoets AJ, Breed WP (2010) Impact of alopecia and scalp cooling on the well-being of breast cancer patients. Psychooncology 19:701–709CrossRefPubMed
5.
Batchelor D (2001) Hair and cancer chemotherapy: consequences and nursing care—a literature study. Eur J Cancer Care (Engl) 10:147–163CrossRef
6.
Hesketh PJ, Batchelor D, Golant M, Lyman GH, Rhodes N, Yardley D (2004) Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches. Support Care Cancer 12:543–549PubMed
7.
van den Hurk CJG, Winstanley J, Boyle F, Young A (2015) Measurement of chemotherapy-induced alopecia—time to change. Support Care Cancer 23:1197–1199CrossRefPubMed
8.
Breed W, van den Hurk CJ, Peerbooms M (2011) Presentation, impact and prevention of chemotherapy induced hair loss: scalp cooling potentials and limitations. Dermatology 6:109–125
9.
Bulow J, Friberg L, Gaardsting O, Hansen M (1985) Frontal subcutaneous blood flow, and epi- and subcutaneous temperatures during scalp cooling in normal man. Scand J Clin Lab Invest 45:505–508CrossRefPubMed
10.
Grevelman EG, Breed WP (2005) Prevention of chemotherapy-induced hair loss by scalp cooling. Ann Oncol 16:352–358CrossRefPubMed
11.
Komen MM, Smorenburg CH, van den Hurk CJ, Nortier JW (2013) Factors influencing the effectiveness of scalp cooling in the prevention of chemotherapy-induced alopecia. Oncologist 18:885–891CrossRefPubMedPubMedCentral
12.
Lemenager M, Lecomte S, Bonneterre ME, Bessa E, Dauba J, Bonneterre J (1997) Effectiveness of cold cap in the prevention of docetaxel-induced alopecia. Eur J Cancer 33:297–300CrossRefPubMed
13.
Chevallier B, Fumoleau P, Kerbrat P, Dieras V, Roche H, Krakowski I, Azli N, Bayssas M, Lentz MA, Van Glabbeke M (1995) Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 13:314–322PubMed
14.
15.
Chan S, Friedrichs K, Noel D, Pinter T, Van Belle S, Vorobiof D, Duarte R, Gil GM, Bodrogi I, Murray E, Yelle L, von Minckwitz G, Korec S, Simmonds P, Buzzi F, Gonzalez MR, Richardson G, Walpole E, Ronzoni M, Murawsky M, Alakl M, Riva A, Crown J (1999) Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 17:2341–2354PubMed
16.
Chang HR, Glaspy J, Allison MA, Kass FC, Elashoff R, Chung DU, Gornbein J (2010) Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment. Cancer 116:4227–4237CrossRefPubMed
17.
Tabernero J, Climent MA, Lluch A, Albanell J, Vermorken JB, Barnadas A, Anton A, Laurent C, Mayordomo JI, Estaun N, Losa I, Guillem V, Garcia-Conde J, Tisaire JL, Baselga J (2004) A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann Oncol 15:1358–1365CrossRefPubMed
18.
Massey CS (2004) A multicentre study to determine the efficacy and patient acceptability of the Paxman Scalp Cooler to prevent hair loss in patients receiving chemotherapy. Eur J Oncol Nurs 8:121–130CrossRefPubMed
19.
van den Hurk CJ, Peerbooms M, van de Poll-Franse LV, Nortier JW, Coebergh JW, Breed WP (2012) Scalp cooling for hair preservation and associated characteristics in 1411 chemotherapy patients—results of the Dutch Scalp Cooling Registry. Acta Oncol 51:497–504CrossRefPubMed
20.
Auvinen PK, Mahonen UA, Soininen KM, Paananen PK, Ranta-Koponen PH, Saavalainen IE, Johansson RT (2010) The effectiveness of a scalp cooling cap in preventing chemotherapy-induced alopecia. Tumori 96:271–275PubMed
21.
Betticher DC, Delmore G, Breitenstein U, Anchisi S, Zimmerli-Schwab B, Muller A, von Moos R, Hugli-Dayer AM, Schefer H, Bodenmann S, Buhler V, Trueb RR (2013) Efficacy and tolerability of two scalp cooling systems for the prevention of alopecia associated with docetaxel treatment. Support Care Cancer 21:2565–2573CrossRefPubMed
22.
van den Hurk CJ, Breed WP, Nortier JW (2012) Short post-infusion scalp cooling time in the prevention of docetaxel-induced alopecia. Support Care Cancer 20:3255–3260CrossRefPubMed
23.
World Health Organization (1979) WHO handbook for reporting results of cancer treatment. World Health Organization, Geneva, p 45
24.
Christodoulou C, Klouvas G, Efstathiou E, Zervakis D, Papazachariou E, Plyta M, Skarlos DV (2002) Effectiveness of the MSC cold cap system in the prevention of chemotherapy-induced alopecia. Oncology 62:97–102CrossRefPubMed
25.
Katsimbri P, Bamias A, Pavlidis N (2000) Prevention of chemotherapy-induced alopecia using an effective scalp cooling system. Eur J Cancer 36:766–771CrossRefPubMed
26.
Ridderheim M, Bjurberg M, Gustavsson A (2003) Scalp hypothermia to prevent chemotherapy-induced alopecia is effective and safe: a pilot study of a new digitized scalp-cooling system used in 74 patients. Support Care Cancer 11:371–377PubMed
27.
Peerbooms M, Breed WPM, van den Hurk CJG (2015) Familiarity, opinions, experiences and knowledge about scalp cooling—a Dutch survey among breast cancer patients and oncological professionals. Asia Pac J Oncol Nurs 2:35–41CrossRef
28.
Chamberlain AJ, Dawber RP (2003) Methods of evaluating hair growth. Australas J Dermatol 44:10–18CrossRefPubMed
29.
Van Neste D (1999) Human scalp hair growth and loss evaluation methods: is there simple and reliable method? Exp Dermatol 8:299–301PubMed
30.
Van Neste MD (2002) Assessment of hair loss: clinical relevance of hair growth evaluation methods. Clin Exp Dermatol 27:358–365CrossRefPubMed
31.
Cohen B (2008) The cross-section trichometer: a new device for measuring hair quantity, hair loss, and hair growth. Dermatol Surg 34:900–910PubMed
32.
Hendriks MA, Geerts PA, Dercksen MW, van den Hurk CJ, Breed WP (2012) Evaluation of Cohen’s cross-section trichometer for measuring hair quantity. Dermatol Surg 38:631–634CrossRefPubMed
33.
Hilton S, Hunt K, Emslie C, Salinas M, Ziebland S (2008) Have men been overlooked? A comparison of young men and women’s experiences of chemotherapy-induced alopecia. Psychooncology 17:577–583CrossRefPubMed
34.
Sweeney C, Chen Y-H, Carducci MA, Liu G (2014) Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial. J Clin Oncol 32:5s (suppl; abstr LBA2)
35.
Van den Hurk CJG (2013) Safety and effectiveness of scalp cooling in cancer patients undergoing cytotoxic treatment. Doctoral thesis, Department of Clinical Oncology, Faculty of Medicine / Leiden University Medical Center (LUMC), Leiden University
Metadata
Title
Results of 20- versus 45-min post-infusion scalp cooling time in the prevention of docetaxel-induced alopecia
Authors
Manon M. C. Komen
Wim P. M. Breed
Carolien H. Smorenburg
Tjeerd van der Ploeg
S. H. Goey
Jacobus J. M. van der Hoeven
Johan W. R. Nortier
Corina J. G. van den Hurk
Publication date
01-06-2016
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 6/2016
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-016-3084-7

Other articles of this Issue 6/2016

Supportive Care in Cancer 6/2016 Go to the issue

Original Article

PRO-ONKO—selection of patient-reported outcome assessments for the clinical use in cancer patients—a mixed-method multicenter cross-sectional exploratory study

Original Article

Effectiveness of acupuncture in rehabilitation of physical and functional disorders of women undergoing breast cancer surgery

Original Article

Systematic review of reduced therapy regimens for children with low risk febrile neutropenia

Original Article

Long-term safety of fentanyl sublingual spray in opioid-tolerant patients with breakthrough cancer pain

Original Article

Psychosocial and physical outcomes of in- and outpatient rehabilitation in prostate cancer patients treated with radical prostatectomy

Original Article

Evaluation of the treatment of chronic chemotherapy-induced peripheral neuropathy using long-wave diathermy and interferential currents: a randomized controlled trial
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits